NCT06390696 Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis
| NCT ID | NCT06390696 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Natural Resources Institute Finland |
| Condition | Atopic Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-05-26 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-05-26 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity. Previous studies indicate association between atopic dermatitis and exposure to natural microbes in childhood. Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis will investigate whether the exposure to microbial diversity in sandbox reduces the symptoms of atopic dermatitis, alters commensal microbiota and modifies immune regulation in children.
Eligibility Criteria
Inclusion Criteria: * Eczema Area and Severity Index ≥ 2 Exclusion Criteria: * Eczema Area and Severity Index \< 2 * Immune deficiencies, i.e., antibody deficiency * Immunosuppressive systematic medications * A disease affecting immune response (e.g., colitis ulcerosa, rheumatoid arthritis, Crohn's disease, diabetes) * Cancer diagnosis * Topical medication for the treatment of atopic dermatitis during the trial * Disability affecting the immune response (e.g. Down's syndrome) * Non-participation in the national vaccine program * Participation in another intervention or follow-up study
Contact & Investigator
Aki Sinkkonen
PRINCIPAL INVESTIGATOR
Natural Resources Institute Finland
Frequently Asked Questions
Who can join the NCT06390696 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 5 Years, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06390696 currently recruiting?
Yes, NCT06390696 is actively recruiting participants. Contact the research team at sanna.hurtola@luke.fi for enrollment information.
Where is the NCT06390696 trial being conducted?
This trial is being conducted at Helsinki, Finland, Tampere, Finland.
Who is sponsoring the NCT06390696 clinical trial?
NCT06390696 is sponsored by Natural Resources Institute Finland. The principal investigator is Aki Sinkkonen at Natural Resources Institute Finland. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.